Developing A Safe Vaccine Against Group A Streptococci
Funder
National Health and Medical Research Council
Funding Amount
$768,530.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified new protective candidate antigens, and we seek to undertake critical non-human primate studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Sanofi Pasteur) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
Clinical And Genomic Aspects Of Staphylococcus Aureus And Other Infectious Diseases In Northern Australia.
Funder
National Health and Medical Research Council
Funding Amount
$421,747.00
Summary
The burden of infectious disease is high in Indigenous populations in northern Australia and patterns of disease differ. My research proposes to deepen our understanding of infectious diseases such as that due to Staphylococcus aureus (golden staph), hepatitis B and influenza by applying cutting-edge technologies (e.g., bacterial genomics) to answer clinically relevant questions. Ultimately I hope to prevent transmission of infections, improve vaccine strategies and find better targets for treat ....The burden of infectious disease is high in Indigenous populations in northern Australia and patterns of disease differ. My research proposes to deepen our understanding of infectious diseases such as that due to Staphylococcus aureus (golden staph), hepatitis B and influenza by applying cutting-edge technologies (e.g., bacterial genomics) to answer clinically relevant questions. Ultimately I hope to prevent transmission of infections, improve vaccine strategies and find better targets for treatment.Read moreRead less
Worldwide Molecular Analysis Of Streptococcus Pyogenes Scarlet Fever Outbreaks
Funder
National Health and Medical Research Council
Funding Amount
$544,041.00
Summary
The microorganism group A Streptococcus (also called GAS or Streptococcus pyogenes) ranks among the top 10 infectious disease killers of humans. Recently, outbreaks of scarlet fever have occurred in both Asia and the United Kingdom, placing a serious strain on health systems. The reasons underlying these outbreaks remain unknown. Our team will lead the global effort to characterise this rise in scarlet fever, and provide recommendations and solutions to health professionals.
Protein Glycan Interactions In Infectious Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$9,182,220.00
Summary
Infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. This is a broad-based collaborative proposal, building on our previous achievements. Its aim is to better understand the dynamic interactions between major disease-causing microbes and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat infectious diseases in the 21st centu ....Infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. This is a broad-based collaborative proposal, building on our previous achievements. Its aim is to better understand the dynamic interactions between major disease-causing microbes and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat infectious diseases in the 21st century.Read moreRead less
Comparative And Functional Genomics Of Human Bacterial Pathogens
Funder
National Health and Medical Research Council
Funding Amount
$601,484.00
Summary
Bacteria have evolved different ways of causing disease in humans. Some bacteria produce toxins that attack the host or they have developed ways to persist in the host by evading immune responses and resisting antibiotics. This project is concerned with understanding how these processes occur and developing preventative strategies for two important groups of bacteria that cause disease in humans, including the bacteria that cause TB and the devastating skin disease Buruli ulcer, and the hospital ....Bacteria have evolved different ways of causing disease in humans. Some bacteria produce toxins that attack the host or they have developed ways to persist in the host by evading immune responses and resisting antibiotics. This project is concerned with understanding how these processes occur and developing preventative strategies for two important groups of bacteria that cause disease in humans, including the bacteria that cause TB and the devastating skin disease Buruli ulcer, and the hospital superbug "Golden Staph".Read moreRead less
Pathogenesis, Treatment And Prevention Of Bacterial Infectious Diseases
Funder
National Health and Medical Research Council
Funding Amount
$852,458.00
Summary
Bacterial infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. My research program aims to better understand the dynamic interactions between major disease-causing bacteria and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat bacterial infectious diseases in the 21st century.
Preclinical Studies Of Group A Streptococcal Vaccine Candidates
Funder
National Health and Medical Research Council
Funding Amount
$532,492.00
Summary
Group A streptococcus causes 520,000 deaths each year. A safe and effective vaccine is not commercially available. We have identified 2 new protective candidate antigens, and we seek to undertake critical preclinical studies to provide further proof-of-concept data. This work will underpin commercial decisions by our industry partner (Wyeth) leading to human trials and the development of a safe group A streptococcal vaccine for human use.
Crohn’s disease (CD), an inflammatory disorder of the gut, is thought to result from an inappropriate response to an environmental trigger, likely gut bacteria. This project will assess differences in microbial communities and host gene expression of early- and late-stage CD tissues. A greater understanding of the differences in mucosal gene expression induced by specific bacteria may provide insights into the pathophysiology of CD, and could conceivably guide therapeutic choices in the future.